Your session is about to expire
← Back to Search
Study Summary
This trial will study whether pridopidine is an effective and safe treatment for early stage Huntington Disease.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 & 3 trial • 163 Patients • NCT04615923Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are we able to enroll new patients in this research project at this time?
"From what is published on clinicaltrials.gov, it appears that recruitment for this particular study has concluded. The trial was initially posted on October 16th 2020 and last updated on November 18th 2021. With that being said, there are 40 other active studies that are still recruiting patients."
Is Pridopidine known to cause serious side effects in patients?
"Since this is a Phase 3 trial, meaning that there is both anecdotal evidence and multiple rounds of safety testing, our team at Power has given Pridopidine a score of 3 for safety."
Are there any other ongoing research projects involving Pridopidine at this time?
"Pridopidine is currently being studied in 3 different trials, with 3 of those trials being in the final stage of testing. Although the majority of the clinical trials for Pridopidine are based in Seattle, 127 different locations across the globe are running tests."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How responsive is this trial?
Typically responds via
Share this study with friends
Copy Link
Messenger